Abstract
The challenges in preventing and controlling tuberculosis are further complicated by the deadly rise of multidrug- resistant tuberculosis (MDR-TB). Recognizing the seriousness of the situation, we initiated a program to screen new agents that would satisfy these unmet needs and have a favorable safety profile. Mycobacteria are well known for their lipid-rich properties. In Mycobacterium tuberculosis, mycolic acid in particular has been established the wall component related to the pathogenesis in the host. There are approximately 250 identified genes related to biosynthesis of the lipid turnover that contain InhA, the main target of isoniazid. Thus, the logical approach for developing a chemotherapy agent against tubercle bacilli included screening compounds that could inhibit the biosyntheses of mycolic acid and that had a novel chemical structure to ensure improved efficacy against MDR-TB. Some of the screening systems established for those purposes and some of the candidates are outlined.
Keywords: Tuberculosis, mycolic acid inhibitor, nitrodehydroimidazooxazole, mycolic acid, BRM test
Current Topics in Medicinal Chemistry
Title: Screening for Novel Antituberculosis Agents that are Effective Against Multidrug Resistant Tuberculosis
Volume: 7 Issue: 5
Author(s): Makoto Matsumoto, Hiroyuki Hashizume, Hidetsugu Tsubouchi, Hirofumi Sasaki, Motohiro Itotani, Hideaki Kuroda, Tatsuo Tomishige, Masanori Kawasaki and Makoto Komatsu
Affiliation:
Keywords: Tuberculosis, mycolic acid inhibitor, nitrodehydroimidazooxazole, mycolic acid, BRM test
Abstract: The challenges in preventing and controlling tuberculosis are further complicated by the deadly rise of multidrug- resistant tuberculosis (MDR-TB). Recognizing the seriousness of the situation, we initiated a program to screen new agents that would satisfy these unmet needs and have a favorable safety profile. Mycobacteria are well known for their lipid-rich properties. In Mycobacterium tuberculosis, mycolic acid in particular has been established the wall component related to the pathogenesis in the host. There are approximately 250 identified genes related to biosynthesis of the lipid turnover that contain InhA, the main target of isoniazid. Thus, the logical approach for developing a chemotherapy agent against tubercle bacilli included screening compounds that could inhibit the biosyntheses of mycolic acid and that had a novel chemical structure to ensure improved efficacy against MDR-TB. Some of the screening systems established for those purposes and some of the candidates are outlined.
Export Options
About this article
Cite this article as:
Matsumoto Makoto, Hashizume Hiroyuki, Tsubouchi Hidetsugu, Sasaki Hirofumi, Itotani Motohiro, Kuroda Hideaki, Tomishige Tatsuo, Kawasaki Masanori and Komatsu Makoto, Screening for Novel Antituberculosis Agents that are Effective Against Multidrug Resistant Tuberculosis, Current Topics in Medicinal Chemistry 2007; 7 (5) . https://dx.doi.org/10.2174/156802607780059727
DOI https://dx.doi.org/10.2174/156802607780059727 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NMR Assisted Antimicrobial Peptide Designing: Structure Based Modifications and Functional Correlation of a Designed Peptide VG16KRKP
Current Medicinal Chemistry Editorial (Thematic Issue: Tropical Rheumatology)
Current Rheumatology Reviews Coumarin-Oxadiazole Derivatives: Synthesis and Pharmacological Properties
Mini-Reviews in Organic Chemistry NMR in the Design of Antibacterials
Current Medicinal Chemistry Pulmonary Delivery of Anti-Tubercular Drugs Using Ligand Anchored pH Sensitive Liposomes for the Treatment of Pulmonary Tuberculosis
Current Drug Delivery Tumor Necrosis Factor: How to Make a Killer Molecule Tumor-Specific?
Current Cancer Drug Targets Biosynthesis of Plant Triterpenoid Saponins: Genes, Enzymes and their Regulation
Mini-Reviews in Organic Chemistry Editorial [Hot topic: Structure-Based Virtual Screening (Guest Editor: Walter Filgueira De Azevedo Jr.)]
Current Drug Targets Identifying Multiple-target Ligands via Computational Chemogenomics Approaches
Current Topics in Medicinal Chemistry Developments in Structural Genomics: Protein Purification and Function Interpretation
Current Genomics HIV Genetic Diversity: Biological and Public Health Consequences
Current HIV Research Willingness of Medical Students to Practice in their Country of Origin after Studies: A Nigerian Perspective
New Emirates Medical Journal Fusing Docking Scoring Functions Improves the Virtual Screening Performance for Discovering Parkinson's Disease Dual Target Ligands
Current Neuropharmacology The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Serum and Bronchoalveolar Lavage Fluid 25(OH)Vitamin D3 Levels in HIV-1 and Tuberculosis: A Cross-Sectional Study from a Tertiary Care Center in North India
Current HIV Research Dietary Interventions in Asthma
Current Pharmaceutical Design Editorial: [A Threat to One is a Threat to All – Biosecurity for the Western World Starts in Developing Countries: Do We Speak the Same Language of Hygiene?]
Inflammation & Allergy - Drug Targets (Discontinued) Weight Loss in Older Persons: New Therapeutic Approaches
Current Pharmaceutical Design Curcumin: A Dietary Phytochemical for Targeting the Phenotype and Function of Dendritic Cells
Current Medicinal Chemistry Simultaneous And Extended Delivery Of Stavudine, Lamivudine And Nevirapine In Fixed Dose Combination Using Sandwiched Osmotic Tablets For Hiv Therapy
Current Drug Delivery